Product Center
Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-27
- Views:
(Summary description)Recently, the Communist Youth League Jiangsu Provincial Committee and the Jiangsu Provincial Department of Human Resources and Social Security officially announced the results of the 20th "Jiangsu Youth May Fourth Medal" selection. The innovative vaccine research team of Ab&B Bio-Tech Co., Ltd. JS has been awarded the honorary title of "Jiangsu Youth May Fourth Medal Collective"!
Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award
(Summary description)Recently, the Communist Youth League Jiangsu Provincial Committee and the Jiangsu Provincial Department of Human Resources and Social Security officially announced the results of the 20th "Jiangsu Youth May Fourth Medal" selection. The innovative vaccine research team of Ab&B Bio-Tech Co., Ltd. JS has been awarded the honorary title of "Jiangsu Youth May Fourth Medal Collective"!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-27 11:34
- Views:
Recently, the Communist Youth League Jiangsu Provincial Committee and the Jiangsu Provincial Department of Human Resources and Social Security officially announced the results of the 20th "Jiangsu Youth May Fourth Medal" selection. The innovative vaccine research team of Ab&B Bio-Tech Co., Ltd. JS has been awarded the honorary title of "Jiangsu Youth May Fourth Medal Collective"!
The Jiangsu Youth May Fourth Medal is the highest honor for young talents in Jiangsu. Our team, as a representative of the biopharmaceutical field, was selected together with outstanding collectives such as the National Integrated Circuit Characteristic Process and Packaging Testing Innovation Center Youth Strike Team, fully demonstrating the high recognition of Ab&B Bio's innovation strength and youth responsibility from all sectors of society.


The team has a total of 87 members, of which 71% are under 35 years old and 11 have a PhD. They have completed the industrialization and successful launch of the only trivalent and quadrivalent influenza subunit vaccines for the entire population in China so far; Continuously tackling innovative vaccines urgently needed in multiple markets, we have obtained IND approvals for four Class I new drugs including recombinant herpes zoster vaccine, achieving a collective breakthrough in "taming adverse reactions".
The team actively promotes the research and development of vaccines related to major infectious diseases. The first monkeypox mRNA vaccine in China to receive clinical trial approval from the US FDA has been proven to have good safety and excellent immunogenicity in monkeys. It can effectively neutralize the monkeypox virus and obtain independent intellectual property rights, demonstrating the collective speed of "racing against the virus". At the same time, the team establishes a quality system that covers the entire product lifecycle, fully ensuring product quality and safety.
In addition, the team actively practices social responsibility - not only by donating vaccines to key populations, but also by exploring the integration of medical and preventive measures, providing evidence-based vaccination for special groups such as pregnant women, children with nephrotic syndrome, and chronic diseases, reducing their risk of infection and severe illness, and supporting the Healthy China strategy with practical actions.

This year marks the beginning of the 15th Five Year Plan and also the beginning of Ab&B Bio's 3rd Five Year Plan. This honor will continue to inspire all young people of Ab&B Bio to remember their instructions and take on responsibilities. We will anchor the vision of "enabling China to use globally innovative vaccines and the world to use high-quality Chinese vaccines", accelerate the breakthrough of innovative vaccine pipelines, build a product matrix driven by "prevention+treatment", and lead the way in the modernization construction of the "Strong, Rich, Beautiful and High" new Jiangsu, contributing youthful strength to the construction of safeguarding people's health!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us